Tigecycline: A rescue drug for multi-drug resistant organisms causing urinary tract infection

The increasing incidence of multi-drug resistant (MDR) organisms causing urinary tract infection (UTI) limits the choice of therapeutic agents to treat UTIs.1–4 It is increasingly becoming difficult for urologists to manage patients with the usual armamentarium of drugs. There is an urgent need to focus on novel options.3 We present the case of UTI with MDR Klebsiella pneumoniae, which was resistant to all conventional drugs. The response to high-dose tigecycline prompted us to report this experience, along with a review of the existing literature.

[1]  Zhiqiang Sun,et al.  Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases , 2019, Medicine.

[2]  R. Geetha,et al.  Etiology and Antimicrobial Susceptibility Pattern of Bacterial Agents from Urinary Tract Infection in a Tertiary Care Centre , 2015 .

[3]  K. Akashi,et al.  Community spread of extended-spectrum β-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis: a long-term study in Japan. , 2013, Journal of medical microbiology.

[4]  M. Levison,et al.  Treatment of Complicated Urinary Tract Infections With an Emphasis on Drug-Resistant Gram-Negative Uropathogens , 2013, Current Infectious Disease Reports.

[5]  D. Nix,et al.  Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. , 2010, The Journal of antimicrobial chemotherapy.

[6]  B. Cunha.  Pharmacokinetic Considerations regarding Tigecycline for Multidrug-Resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii Urosepsis , 2009, Journal of Clinical Microbiology.

[7]  J. S. Bradley,et al.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  U. Nagele,et al.  Treatment with Tigecycline of Recurrent Urosepsis Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli , 2007, Journal of Clinical Microbiology.

[9]  A. Howe,et al.  Occurrence of Tetracycline Resistance Genes among Escherichia coli Isolates from the Phase 3 Clinical Trials for Tigecycline , 2007, Antimicrobial Agents and Chemotherapy.

[10]  D. Livermore.  Tigecycline: what is it, and where should it be used? , 2005, The Journal of antimicrobial chemotherapy.

[11]  Ronald N. Jones,et al.  Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. , 2005, Diagnostic microbiology and infectious disease.

[12]  S. Troy,et al.  Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects , 2005, Antimicrobial Agents and Chemotherapy.